AtheroNova
Irvine
About AtheroNova
AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The company is entering into a research agreement for its second laboratory animal study at the Cedars-Sinai Heart Institute's Division of Cardiology in conjunction with a major university to validate the findings of its initial study and prepare for human trials. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.4M
- Funding stage: IPO
- Last round: Post-IPO Debt (Sep 2014)
- Ticker: otcpink:AHROQ
- Website: atheronova.com
- Phone: +1 9494761122
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/atheronova-2033486 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.